MLST8

Summary

MLST8 (MTOR associated protein MLST8, HGNC:24825) is a protein-coding gene on chromosome 16p13.3, encoding Target of rapamycin complex subunit LST8 (Q9BVC4). Subunit of both mTORC1 and mTORC2, which regulates cell growth and survival in response to nutrient and hormonal signals. mTORC1 is activated in response to growth factors or amino acids. It is a selective cancer dependency (DepMap: 69.5% of cell lines).

Enables protein serine/threonine kinase activator activity and protein-macromolecule adaptor activity. Contributes to protein serine/threonine kinase activity. Involved in TOR signaling; positive regulation of TOR signaling; and regulation of actin cytoskeleton organization. Part of TORC1 complex and TORC2 complex.

Source: NCBI Gene 64223 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 48 total
• GTEx eGene: eQTL in 48 tissues, sQTL in 50 (q < 0.05)
• Drug target: yes — 1 via a complex or family; 13 molecules with ChEMBL bioactivity (top 2% of genes corpus-wide)
• Cancer dependency (DepMap): dependent in 69.5% of screened cell lines
• Constraint (gnomAD): pLI 0.02 (LoF-tolerant), LOEUF 0.68 (unconstrained)
• MANE Select transcript: NM_022372

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24825
Approved symbol	MLST8
Name	MTOR associated protein MLST8
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	Lst8, Pop3, GBL, GbetaL
Ensembl gene	ENSG00000167965
Ensembl biotype	protein_coding
OMIM	612190
Entrez	64223

Gene structure

Transcript identifiers

Ensembl transcripts: 93 — 39 protein_coding, 37 nonsense_mediated_decay, 12 retained_intron, 5 protein_coding_CDS_not_defined

MANE Select: ENST00000569417

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 4, TSL 2: 11, TSL 3: 6, TSL 4: 8, TSL 5: 6

ENST00000569417, ENST00000301724, ENST00000382450, ENST00000397124, ENST00000561651, ENST00000562043, ENST00000562239, ENST00000562352, ENST00000562392, ENST00000562479, ENST00000562844, ENST00000562851, ENST00000563067, ENST00000563107, ENST00000563179, ENST00000564088, ENST00000564294, ENST00000564319, ENST00000564679, ENST00000565250, ENST00000565269, ENST00000565330, ENST00000565687, ENST00000565717, ENST00000565926, ENST00000566653, ENST00000566835, ENST00000567282, ENST00000567623, ENST00000567928, ENST00000568194, ENST00000568542, ENST00000569457, ENST00000569848, ENST00000570224, ENST00000878720, ENST00000878721, ENST00000878722, ENST00000878723, ENST00000878724, ENST00000878725, ENST00000878726, ENST00000878727, ENST00000878728, ENST00000878729, ENST00000878730, ENST00000878731, ENST00000878732, ENST00000878733, ENST00000878734, ENST00000878735, ENST00000878736, ENST00000878737, ENST00000878738, ENST00000945250, ENST00000945251, ENST00000945252, ENST00000945253, ENST00000945254, ENST00001008646, ENST00001008648, ENST00001008649, ENST00001008650, ENST00001008651, ENST00001008652, ENST00001008653, ENST00001037921, ENST00001037922, ENST00001037923, ENST00001037924, ENST00001037925, ENST00001037926, ENST00001037927, ENST00001037928, ENST00001037929, ENST00001037930, ENST00001037931, ENST00001037932, ENST00001037933, ENST00001037934, ENST00001037935, ENST00001082229, ENST00001082230, ENST00001082231, ENST00001082232, ENST00001082233, ENST00001082234, ENST00001082235, ENST00001082236, ENST00001082237, ENST00001098771, ENST00001112993, ENST00001133167

RefSeq mRNA: 7 — MANE Select: NM_022372 NM_001199173, NM_001199174, NM_001199175, NM_001352057, NM_001352059, NM_001352060, NM_022372

CCDS: CCDS10462, CCDS58409

Canonical transcript exons

ENST00000569417 — 9 exons

Exon	Start	End
ENSE00002613104	2205454	2205512
ENSE00003495720	2206031	2206214
ENSE00003611614	2207035	2207110
ENSE00003616825	2207193	2207345
ENSE00003619428	2206358	2206409
ENSE00003628750	2208210	2208334
ENSE00003665527	2208450	2208613
ENSE00003693495	2206497	2206659
ENSE00004782172	2208759	2209453

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 97.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 56.5200 / max 235.9299, expressed in 1813 samples.

Highest expression (Bgee): hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex, frontal lobe, cerebellum.

Genetic regulation across tissues (GTEx eQTL / sQTL)

MLST8 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 48 tissues and its splicing (sQTL) in 50 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 98 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Muscle Skeletal	sqtl	1.4e-99	-1.01	16:2205221:C:T
Cells Cultured fibroblasts	eqtl	8.9e-96	+0.67	16:2205762:A:C
Thyroid	sqtl	1.4e-78	-0.91	16:2206046:AC:A
Cells Cultured fibroblasts	sqtl	3.7e-72	-1.01	16:2206325:C:T
Skin Sun Exposed Lower leg	sqtl	1.2e-62	-0.89	16:2206046:AC:A
Skin Not Sun Exposed Suprapubic	sqtl	6.9e-60	-0.91	16:2205221:C:T
Thyroid	eqtl	2.0e-59	+0.37	16:2206460:C:G
Testis	sqtl	8.8e-52	-1.06	16:2206046:AC:A
Esophagus Mucosa	sqtl	5.3e-49	-0.93	16:2206325:C:T
Nerve Tibial	sqtl	7.1e-49	-0.83	16:2206046:AC:A
Adipose Subcutaneous	sqtl	2.3e-48	-0.80	16:2205221:C:T
Cells EBV-transformed lymphocytes	sqtl	6.0e-41	-1.06	16:2206046:AC:A
Brain Cerebellum	sqtl	1.3e-40	-1.12	16:2207104:C:G
Brain Cerebellar Hemisphere	sqtl	5.8e-39	-1.06	16:2207104:C:G
Nerve Tibial	eqtl	7.3e-39	+0.31	16:2205221:C:T
Artery Tibial	eqtl	1.2e-38	+0.30	16:2206046:AC:A
Whole Blood	sqtl	2.0e-38	-0.73	16:2207104:C:G
Breast Mammary Tissue	sqtl	2.8e-38	-0.85	16:2206046:AC:A
Skin Sun Exposed Lower leg	eqtl	6.4e-38	+0.22	16:2205221:C:T
Skin Not Sun Exposed Suprapubic	eqtl	2.7e-37	+0.27	16:2205221:C:T

FANTOM5 promoters

8 alternative TSS:

Promoter ID	TPM avg	Samples expressed
152207	30.6683	1804
152208	18.1108	1781
152210	3.9149	1472
152204	1.5100	853
152206	1.0326	627
152209	0.7036	455
152213	0.3797	196
152205	0.2001	97

Top tissues by expression

showing 100 of 286 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.10	gold quality
cerebellar hemisphere	UBERON:0002245	96.64	gold quality
cerebellar cortex	UBERON:0002129	96.56	gold quality
right frontal lobe	UBERON:0002810	95.95	gold quality
cerebellum	UBERON:0002037	95.29	gold quality
prefrontal cortex	UBERON:0000451	95.13	gold quality
anterior cingulate cortex	UBERON:0009835	95.04	gold quality
cingulate cortex	UBERON:0003027	95.02	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.10	gold quality
apex of heart	UBERON:0002098	93.80	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.73	gold quality
amygdala	UBERON:0001876	93.34	gold quality
nucleus accumbens	UBERON:0001882	93.25	gold quality
left testis	UBERON:0004533	92.95	gold quality
frontal cortex	UBERON:0001870	92.86	gold quality
neocortex	UBERON:0001950	92.85	gold quality
right lobe of thyroid gland	UBERON:0001119	92.82	gold quality
gastrocnemius	UBERON:0001388	92.81	gold quality
putamen	UBERON:0001874	92.70	gold quality
right adrenal gland cortex	UBERON:0035827	92.59	gold quality
caudate nucleus	UBERON:0001873	92.58	gold quality
right testis	UBERON:0004534	92.58	gold quality
right adrenal gland	UBERON:0001233	92.56	gold quality
mucosa of transverse colon	UBERON:0004991	92.49	gold quality
body of pancreas	UBERON:0001150	92.44	gold quality
left adrenal gland	UBERON:0001234	92.43	gold quality
left adrenal gland cortex	UBERON:0035825	92.34	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.33	gold quality
muscle of leg	UBERON:0001383	92.28	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.13	gold quality
left lobe of thyroid gland	UBERON:0001120	91.92	gold quality
adenohypophysis	UBERON:0002196	91.60	gold quality
adrenal cortex	UBERON:0001235	91.47	gold quality
right uterine tube	UBERON:0001302	91.20	gold quality
spinal cord	UBERON:0002240	91.14	gold quality
body of stomach	UBERON:0001161	91.13	gold quality
thyroid gland	UBERON:0002046	91.07	gold quality
metanephros cortex	UBERON:0010533	91.02	gold quality
telencephalon	UBERON:0001893	91.01	gold quality
cerebral cortex	UBERON:0000956	90.99	gold quality
brain	UBERON:0000955	90.95	gold quality
testis	UBERON:0000473	90.94	gold quality
ganglionic eminence	UBERON:0004023	90.84	gold quality
forebrain	UBERON:0001890	90.81	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.80	gold quality
stromal cell of endometrium	CL:0002255	90.73	gold quality
right lobe of liver	UBERON:0001114	90.59	gold quality
pituitary gland	UBERON:0000007	90.51	gold quality
hypothalamus	UBERON:0001898	90.49	gold quality
granulocyte	CL:0000094	90.37	gold quality
skin of leg	UBERON:0001511	90.11	gold quality
adrenal gland	UBERON:0002369	90.09	gold quality
skin of abdomen	UBERON:0001416	89.88	gold quality
right atrium auricular region	UBERON:0006631	89.87	gold quality
left ovary	UBERON:0002119	89.81	gold quality
ventricular zone	UBERON:0003053	89.78	gold quality
lower esophagus mucosa	UBERON:0035834	89.69	gold quality
transverse colon	UBERON:0001157	89.68	gold quality
esophagus mucosa	UBERON:0002469	89.67	gold quality
Ammon’s horn	UBERON:0001954	89.64	gold quality
heart left ventricle	UBERON:0002084	89.63	gold quality
right ovary	UBERON:0002118	89.53	gold quality
minor salivary gland	UBERON:0001830	89.49	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.40	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	89.40	gold quality
skeletal muscle organ	UBERON:0014892	89.20	gold quality
muscle organ	UBERON:0001630	89.19	gold quality
cardiac ventricle	UBERON:0002082	89.07	gold quality
body of uterus	UBERON:0009853	89.07	gold quality
esophagus	UBERON:0001043	89.06	gold quality
muscle layer of sigmoid colon	UBERON:0035805	88.95	gold quality
cortical plate	UBERON:0005343	88.92	gold quality
lower esophagus	UBERON:0013473	88.90	gold quality
lower esophagus muscularis layer	UBERON:0035833	88.90	gold quality
spleen	UBERON:0002106	88.64	gold quality
stomach	UBERON:0000945	88.55	gold quality
left uterine tube	UBERON:0001303	88.47	gold quality
left coronary artery	UBERON:0001626	88.44	gold quality
cardiac atrium	UBERON:0002081	88.42	gold quality
substantia nigra	UBERON:0002038	88.41	gold quality
gall bladder	UBERON:0002110	88.40	gold quality
type B pancreatic cell	CL:0000169	88.37	gold quality
temporal lobe	UBERON:0001871	88.32	gold quality
ectocervix	UBERON:0012249	88.23	gold quality
pancreas	UBERON:0001264	88.17	gold quality
upper lobe of left lung	UBERON:0008952	88.14	gold quality
tibial nerve	UBERON:0001323	88.13	gold quality
endocervix	UBERON:0000458	88.05	gold quality
olfactory bulb	UBERON:0002264	88.00	gold quality
saliva-secreting gland	UBERON:0001044	87.99	gold quality
omental fat pad	UBERON:0010414	87.90	gold quality
mouth mucosa	UBERON:0003729	87.88	gold quality
peritoneum	UBERON:0002358	87.85	gold quality
heart	UBERON:0000948	87.82	gold quality
midbrain	UBERON:0001891	87.77	gold quality
coronary artery	UBERON:0001621	87.76	gold quality
small intestine	UBERON:0002108	87.69	gold quality
mucosa of stomach	UBERON:0001199	87.66	gold quality
fundus of stomach	UBERON:0001160	87.53	gold quality
embryo	UBERON:0000922	87.33	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6524	no	142.43
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Postcentral gyrus	tissue	44.9
Skeletal muscle	tissue	36.9	medium
Hippocampus	tissue	34.2	low
Locus coeruleus	tissue	32.7
Caudate putamen	tissue	25.7
Nucleus accumbens	tissue	25.0
Frontal cortex	tissue	24.8
Pancreas	tissue	23.4	medium
Pituitary gland	tissue	21.1
Choroid plexus	tissue	21.0
Tongue	tissue	20.3
Salivary gland	tissue	18.5	medium
Vagina	tissue	15.8	medium
Testis	tissue	15.0	medium
Ovary	tissue	14.7	low
Heart muscle	tissue	13.4	medium
Thyroid gland	tissue	13.2	medium
Adrenal gland	tissue	12.7	medium
Bone marrow	tissue	12.6	medium
Parathyroid gland	tissue	12.5	medium
Superior colliculi	tissue	11.7
Duodenum	tissue	11.7	medium
Cerebral cortex	tissue	11.6	medium
Thalamus	tissue	11.6
Somatosensory cortex	tissue	11.6
Cerebellum	tissue	11.5	medium
Fallopian tube	tissue	11.5	medium
Stomach 1	tissue	11.2	medium
Small intestine	tissue	10.9	medium
Midbrain	tissue	10.8
Motor cortex	tissue	10.7
Putamen	tissue	10.7
Pons	tissue	10.5
Occipital cortex	tissue	10.5
Placenta	tissue	10.4	medium
Hippocampal formation	tissue	10.4
Basal ganglia	tissue	10.3	medium
Olfactory bulb	tissue	10.3
Esophagus	tissue	10.2	medium
Skin 1	tissue	10.0	medium
Prefrontal cortex	tissue	10.0
Colon	tissue	9.9	medium
Medulla oblongata	tissue	9.9
Retrosplenial and cingulate cortex	tissue	9.9
Lymph node	tissue	9.8	medium
Temporal cortex	tissue	9.8
Spinal cord	tissue	9.6
Entorhinal cortex	tissue	9.6
Insular cortex	tissue	9.4
Prostate	tissue	9.3	medium
Ventral forebrain	tissue	9.3
Retrosplenial cortex	tissue	9.3
Appendix	tissue	9.3	medium
Substantia nigra	tissue	9.1
Liver	tissue	9.0	medium
Kidney	tissue	9.0	medium
Thymus	tissue	9.0
Septum	tissue	9.0
Hypothalamus	tissue	8.8
Gallbladder	tissue	8.6	medium

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Precentral gyrus (47.1), Supplementary motor cortex (39.9), Postcentral gyrus, middle (39.6), Somatomor cortex, precentral gyrus (white matter) (37.9), Inferior parietal lobule (37.5).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting MLST8 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

25 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-4529-5P	96.74	65.77	569
HSA-MIR-9900	96.06	65.48	557
HSA-MIR-4520-5P	93.54	65.23	140

Functional genomics

gnomAD constraint: pLI 0.0205, LOEUF 0.679, missense Z 0.843 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000569417 — one region, missense o/e 0.93. DepMap (CRISPR cell-line fitness): dependent in 69.5% of screened cell lines.

Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): SU-DHL-4 (-2.073), GAMG (-2.04), IGR-39 (-1.991), EWS502 (-1.876), KE-37 (-1.824), BT-549 (-1.806), LN-319 (-1.74), ONCO-DG-1 (-1.703), VM-CUB1 (-1.688), SNU-8 (-1.662), MFE-280 (-1.645), OUMS-23 (-1.574), NCI-H520 (-1.568), Saos-2 (-1.535), KARPAS-422 (-1.531).

Literature-anchored findings (GeneRIF, showing 16)

• show that E2F1 is capable of inducing growth by regulating mTORC1 activity (PMID:21283628)
• results suggest that GRp58/ERp57 is involved in the assembly of mTORC1 and positively regulates mTORC1 signaling at the cytosol and the cytosolic side of the endoplasmic reticulum (PMID:21321085)
• Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4 (PMID:21454807)
• An essential role of mTORC1 in autophagy inhibition in cell-free system in which, membrane association of Barkor/Atg14(L), a specific autophagosome-binding protein, is suppressed by cytosol from nutrient-rich medium, is shown. (PMID:22258093)
• MLST8 polymorphism is associated with gastric cancer. (PMID:23423739)
• The results obtained indicate that mLST8 bridges between CAD and mTOR, and plays a role in the signaling mechanism where CAD is regulated in the mTOR pathway through the association with mLST8. (PMID:23594158)
• Amino acids promote mTORC1 activation without altering Rag GTP charging. (PMID:24337580)
• MLST8 upregulation may contribute to tumor progression. (PMID:25906254)
• Data suggest MTMR3 has multiple functions in regulation of autophagy; one mechanism appears to be direct interaction between MTMR3 and mTORC1 (MTOR, mLST8, raptor) which inhibits phosphorylation activity of mTORC1; MTMR3 is localized to Golgi apparatus. (PMID:26787466)
• Autophagy regulates c-MET phosphorylation via an mTORC2-dependent mechanism. (PMID:28475179)
• NEAT1 was potentially communicated with mTOR signaling target protein mLST8 via the association with miR-181b in type 2 diabetes mellitus. (PMID:28643459)
• Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma. (PMID:32157528)
• ASO Author Reflections: mLST8 is a Prognostic Biomarker and Involved in Tumor Progression in Hepatocellular Carcinoma. (PMID:32166592)
• STAT3-mediated MLST8 gene expression regulates cap-dependent translation in cancer cells. (PMID:32495998)
• CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma. (PMID:34741373)
• Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m(6)A demethylation of EIF4EBP1 and MLST8 mRNA. (PMID:35579750)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mlst8	ENSDARG00000003167
mus_musculus	Mlst8	ENSMUSG00000024142
rattus_norvegicus	Mlst8	ENSRNOG00000009667
drosophila_melanogaster	Lst8	FBGN0264691
caenorhabditis_elegans	mlst-8	WBGENE00015697

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1929514) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 11 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal heart development	1
abnormal brain development	1
abnormal telencephalon development	1
internal hemorrhage	1
decreased embryo size	1
abnormal placenta morphology	1
abnormal vitelline vasculature morphology	1
embryonic growth retardation	1
dilated vasculature	1
embryonic lethality during organogenesis, complete penetrance	1
thick placenta labyrinth	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RAW8	99.9%	Diamond
Bos taurus	Q32PG3	99.7%	Diamond
Xenopus tropicalis	Q5I0B4	99.7%	Diamond
Xenopus laevis	Q6PA72	99.7%	Diamond
Gallus gallus	Q5F3K4	97.9%	Diamond
Macaca fascicularis	Q4R2Z6	91.7%	Diamond
Drosophila pseudoobscura pseudoobscura	Q29HG9	91.1%	Diamond
Culex quinquefasciatus	B0X2V9	84.9%	Diamond
Arabidopsis thaliana	F4IIK6	77.4%	Diamond
Oryza sativa Japonica Group	Q9AYE4	77.0%	Diamond
Schizosaccharomyces pombe 972h-	O74184	65.2%	Diamond
Saccharomyces cerevisiae S288C	P41318	65.2%	Diamond
Dictyostelium discoideum	Q54D08	63.6%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MIR3180-5	ncRNA	100500916
RAB26	protein-coding	25837
SNORD60	snoRNA	26788
BRICD5	protein-coding	283870
CASKIN1	protein-coding	57524
TRAF7	protein-coding	84231
DNASE1L2	protein-coding	1775
E4F1	protein-coding	1877
PGP	protein-coding	283871
SNHG19	ncRNA	100507303
ECI1-AS1	ncRNA	123706507
ECI1	protein-coding	1632

Protein

Protein identifiers

Target of rapamycin complex subunit LST8 — Q9BVC4 (reviewed: Q9BVC4)

Alternative names: G protein beta subunit-like, Mammalian lethal with SEC13 protein 8

All UniProt accessions (11): Q9BVC4, A0A0A0MR05, H3BM50, H3BN58, H3BPT1, H3BPU5, H3BQ74, H3BR25, H3BR38, H3BSZ4, I3L2E7

UniProt curated annotations — full annotation on UniProt →

Function. Subunit of both mTORC1 and mTORC2, which regulates cell growth and survival in response to nutrient and hormonal signals. mTORC1 is activated in response to growth factors or amino acids. In response to nutrients, mTORC1 is recruited to the lysosome membrane and promotes protein, lipid and nucleotide synthesis by phosphorylating several substrates, such as ribosomal protein S6 kinase (RPS6KB1 and RPS6KB2) and EIF4EBP1 (4E-BP1). In the same time, it inhibits catabolic pathways by phosphorylating the autophagy initiation components ULK1 and ATG13, as well as transcription factor TFEB, a master regulators of lysosomal biogenesis and autophagy. The mTORC1 complex is inhibited in response to starvation and amino acid depletion. Within mTORC1, MLST8 interacts directly with MTOR and enhances its kinase activity. In nutrient-poor conditions, stabilizes the MTOR-RPTOR interaction and favors RPTOR-mediated inhibition of MTOR activity. As part of the mTORC2 complex, transduces signals from growth factors to pathways involved in proliferation, cytoskeletal organization, lipogenesis and anabolic output. mTORC2 is also activated by growth factors, but seems to be nutrient-insensitive. In response to growth factors, mTORC2 phosphorylates and activates AGC protein kinase family members, including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and SGK1. mTORC2 functions upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 activation by mediating phosphorylation of different sites depending on the context, such as ‘Thr-450’, ‘Ser-473’, ‘Ser-477’ or ‘Thr-479’, facilitating the phosphorylation of the activation loop of AKT1 on ‘Thr-308’ by PDPK1/PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at ‘Ser-422’. mTORC2 also modulates the phosphorylation of PRKCA on ‘Ser-657’. Within mTORC2, MLST8 acts as a bridge between MAPKAP1/SIN1 and MTOR.

Subunit / interactions. Part of the mechanistic target of rapamycin complex 1 (mTORC1) which contains MTOR, MLST8 and RPTOR. mTORC1 associates with AKT1S1/PRAS40, which inhibits its activity. mTORC1 binds to and is inhibited by FKBP12-rapamycin. Within mTORC1, interacts directly with MTOR and RPTOR. Component of the mechanistic target of rapamycin complex 2 (mTORC2), consisting in two heterotretramers composed of MTOR, MLST8, RICTOR and MAPKAP1/SIN1. Contrary to mTORC1, mTORC2 does not bind to and is not sensitive to FKBP12-rapamycin. mTORC1 and mTORC2 associate with DEPTOR, which regulates their activity. Interacts with RHEB. Interacts with MEAK7. Interacts with SIK3. Interacts with SLC38A7; this interaction promotes the recruitment of mTORC1 to the lysosome and its subsequent activation.

Subcellular location. Lysosome membrane. Cytoplasm.

Tissue specificity. Broadly expressed, with highest levels in skeletal muscle, heart and kidney.

Post-translational modifications. Phosphorylation at Thr-51 by CDK1 promotes ubiquitination by the SCF(FBXW7) complex, followed by degradation. Ubiquitination by the SCF(FBXW7) and SCF(FBXW11) complexes following phosphorylation at Thr-51 by CDK1, leads to its degradation by the proteasome. Ubiquitination at Lys-305 and Lys-313 by TRAF2 via ‘Lys-63’-linked polyubiquitin chains inhibits formation of the mTORC2 complex, while promoting formation of the mTORC1 complex: ubiquitination disrupts the interaction between MLST8 and MAPKAP1/SIN1 to favor mTORC1 assembly. Deubiquitination at Lys-305 and Lys-313 by OTUD7B promotes MLST8 interaction with MAPKAP1/SIN1, facilitating mTORC2 assembly. Sumoylation with SUMO1, SUMO2 and SUMO3 promotes assembly of both mTORC1 and mTORC2 complexes.

Similarity. Belongs to the WD repeat LST8 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9BVC4-1	1	yes
Q9BVC4-3	2
Q9BVC4-4	3
Q9BVC4-5	4

RefSeq proteins (7): NP_001186102, NP_001186103, NP_001186104, NP_001338986, NP_001338988, NP_001338989, NP_071767* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR011047	Quinoprotein_ADH-like_sf	Homologous_superfamily
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR037588	MLST8	Family

Pfam: PF00400

UniProt features (79 total): strand 33, mutagenesis site 11, cross-link 8, repeat 7, splice variant 5, turn 5, modified residue 4, sequence conflict 3, chain 1, sequence variant 1, helix 1

Structure

Experimental structures (PDB)

showing 30 of 45 structures by resolution:

PDB	Title	Method	Resolution (Å)
9T94	cryo-EM structure of AKT phosphorylated mTOR complex 2, focused on a single protomer	ELECTRON MICROSCOPY	2.6
9ZBK	mTORC2 in complex with Akt1	ELECTRON MICROSCOPY	2.6
8ERA	RMC-5552 in complex with mTORC1 and FKBP12	ELECTRON MICROSCOPY	2.86
9T93	cryo-EM structure of autophosphorylated mTOR complex 2, focused on a single protomer	ELECTRON MICROSCOPY	2.86
6ZWO	cryo-EM structure of human mTOR complex 2, focused on one half	ELECTRON MICROSCOPY	3
9T7J	cryo-EM structure of AKT phosphorylated mTOR complex 2, overall refinement	ELECTRON MICROSCOPY	3
9TDT	cryo-EM structure of dephosphorylated mTOR complex 2, focused on a single protomer	ELECTRON MICROSCOPY	3
5WBY	Crystal structure of mTOR(deltaN)-mLST8-PRAS40(beta-strand) complex	X-RAY DIFFRACTION	3.1
9T92	cryo-EM structure of autophosphorylated mTOR complex 2, overall refinement	ELECTRON MICROSCOPY	3.1
9ED7	Active state of mTOR on membrane	ELECTRON MICROSCOPY	3.16
4JSN	structure of mTORdeltaN-mLST8 complex	X-RAY DIFFRACTION	3.2
6ZWM	cryo-EM structure of human mTOR complex 2, overall refinement	ELECTRON MICROSCOPY	3.2
7PE8	cryo-EM structure of DEPTOR bound to human mTOR complex 2, focussed on one protomer	ELECTRON MICROSCOPY	3.2
7UXC	cryo-EM structure of the mTORC1-TFEB-Rag-Ragulator complex with symmetry expansion	ELECTRON MICROSCOPY	3.2
7UXH	cryo-EM structure of the mTORC1-TFEB-Rag-Ragulator complex	ELECTRON MICROSCOPY	3.2
9ZBJ	Cryo-EM structure of human apo mTORC2	ELECTRON MICROSCOPY	3.2
6BCX	mTORC1 structure refined to 3.0 angstroms	ELECTRON MICROSCOPY	3.23
9ED4	A composite map of mTORC1-Rag-Ragultor-4EBP1 on membrane	ELECTRON MICROSCOPY	3.23
7TZO	The apo structure of human mTORC2 complex	ELECTRON MICROSCOPY	3.28
4JSP	structure of mTORDeltaN-mLST8-ATPgammaS-Mg complex	X-RAY DIFFRACTION	3.3
9TDS	cryo-EM structure of dephosphorylated mTOR complex 2, overall refinement	ELECTRON MICROSCOPY	3.3
8RCK	CryoEM structure of mTORC1 with a paediatric kidney cancer-associated 1455-EWED-1458 …	ELECTRON MICROSCOPY	3.4
7PE7	cryo-EM structure of DEPTOR bound to human mTOR complex 2, overall refinement	ELECTRON MICROSCOPY	3.41
5WBU	Crystal structure of mTOR(deltaN)-mLST8-PRAS40(alpha-helix & beta-strand) complex	X-RAY DIFFRACTION	3.42
4JT5	mTORdeltaN-mLST8-pp242 complex	X-RAY DIFFRACTION	3.45
4JSV	mTOR kinase structure, mechanism and regulation.	X-RAY DIFFRACTION	3.5
4JSX	structure of mTORDeltaN-mLST8-Torin2 complex	X-RAY DIFFRACTION	3.5
4JT6	structure of mTORDeltaN-mLST8-PI-103 complex	X-RAY DIFFRACTION	3.6
9ED8	Intermediate state of mTOR on membrane	ELECTRON MICROSCOPY	3.61
7PEB	cryo-EM structure of DEPTOR bound to human mTOR complex 1, focussed on one protomer	ELECTRON MICROSCOPY	3.67

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BVC4-F1	92.15	0.82

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm; cell junctions; golgi apparatus

Antibody reliability (HPA): IH approved · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12)

Type	Positions
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo3)	86, 215, 245, 261, 305
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in ubiquitin)	305, 313
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo1)	313
N-acetylmethionine	1, 1
Phosphoserine	7
Phosphothreonine	51

Mutagenesis-validated functional residues (11)

Position	Phenotype
44–46	in mut1; impaired assembly of the mtorc2 complex.
51	reduced ubiquitination by the scf(fbxw7) complex.
55	does not affect ubiquitination by the scf(fbxw7) complex.
72	impairs interaction with mtor.
192	abolishes interaction with mtor.
213–215	decreased sumoylation; when associated with 305-r–r-313.
272–274	in mut2; impaired assembly of the mtorc2 complex.
305–313	decreased sumoylation; when associated with 213-r–r-215.
305	elevated assembly of mtorc2 complex; when associated with r-313. decreased sumoylation.
313	elevated assembly of mtorc2 complex; when associated with r-305. decreased sumoylation.
320	impairs interaction with mtor.

Function

Pathways and Gene Ontology

Reactome pathways

15 curated (TAS) of 41; 5 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

41 pathways:

ID	Pathway	Evidence
R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer ⚕	curated
R-HSA-9920951	Dengue virus modulates apoptosis ⚕	curated
R-HSA-9639288	Amino acids regulate mTORC1	curated
R-HSA-389357	CD28 dependent PI3K/Akt signaling	curated
R-HSA-380972	Energy dependent regulation of mTOR by LKB1-AMPK	curated
R-HSA-3371571	HSF1-dependent transactivation	curated
R-HSA-9856530	High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	curated
R-HSA-165159	MTOR signalling	curated
R-HSA-1632852	Macroautophagy	curated
R-HSA-1257604	PIP3 activates AKT signaling	curated
R-HSA-8943724	Regulation of PTEN gene transcription	curated
R-HSA-6804757	Regulation of TP53 Degradation	curated
R-HSA-5628897	TP53 Regulates Metabolic Genes	curated
R-HSA-5218920	VEGFR2 mediated vascular permeability	curated
R-HSA-166208	mTORC1-mediated signalling	curated
R-HSA-1643685	Disease ⚕	—
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers ⚕	—
R-HSA-2219528	PI3K/AKT Signaling in Cancer ⚕	—
R-HSA-1280218	Adaptive Immune System	—
R-HSA-9612973	Autophagy	—
R-HSA-3371556	Cellular response to heat stress	—
R-HSA-9711097	Cellular response to starvation	—
R-HSA-9855142	Cellular responses to mechanical stimuli	—
R-HSA-8953897	Cellular responses to stimuli	—
R-HSA-2262752	Cellular responses to stress	—
R-HSA-389356	Co-stimulation by CD28	—
R-HSA-74160	Gene expression (Transcription)	—
R-HSA-212436	Generic Transcription Pathway	—
R-HSA-168256	Immune System	—
R-HSA-9006925	Intracellular signaling by second messengers	—
R-HSA-6807070	PTEN Regulation	—
R-HSA-73857	RNA Polymerase II Transcription	—
R-HSA-388841	Regulation of T cell activation by CD28 family	—
R-HSA-5633007	Regulation of TP53 Activity	—
R-HSA-6806003	Regulation of TP53 Expression and Degradation	—
R-HSA-9860931	Response of endothelial cells to shear stress	—
R-HSA-162582	Signal Transduction	—
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	—
R-HSA-194138	Signaling by VEGF	—
R-HSA-3700989	Transcriptional Regulation by TP53	—
R-HSA-4420097	VEGFA-VEGFR2 Pathway	—

MSigDB gene sets: 320 (showing top): GOBP_REGULATION_OF_AUTOPHAGY, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOCC_VACUOLAR_MEMBRANE, GOBP_NADPPLUS_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TOR_SIGNALING, GOBP_GROWTH, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, TGACCTY_ERR1_Q2, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS

GO Biological Process (16): DNA damage response (GO:0006974), cytoskeleton organization (GO:0007010), negative regulation of autophagy (GO:0010507), positive regulation of cell growth (GO:0030307), cellular response to nutrient levels (GO:0031669), TOR signaling (GO:0031929), positive regulation of TOR signaling (GO:0032008), regulation of actin cytoskeleton organization (GO:0032956), TORC1 signaling (GO:0038202), TORC2 signaling (GO:0038203), negative regulation of apoptotic process (GO:0043066), positive regulation of glycolytic process (GO:0045821), positive regulation of lipid biosynthetic process (GO:0046889), cellular response to hypoxia (GO:0071456), cellular response to osmotic stress (GO:0071470), positive regulation of pentose-phosphate shunt (GO:1905857)

GO Molecular Function (4): protein-macromolecule adaptor activity (GO:0030674), protein serine/threonine kinase activator activity (GO:0043539), protein serine/threonine kinase activity (GO:0004674), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), lysosomal membrane (GO:0005765), cytosol (GO:0005829), TORC1 complex (GO:0031931), TORC2 complex (GO:0031932)

Reactome top-level categories

16 top-level categories:

Category	Pathways
MTOR signalling	2
Intracellular signaling by second messengers	1
Autophagy	1
Signal Transduction	1
Cellular response to heat stress	1
Co-stimulation by CD28	1
VEGFA-VEGFR2 Pathway	1
Transcriptional Regulation by TP53	1
PI3K/AKT Signaling in Cancer	1
Regulation of TP53 Expression and Degradation	1
PTEN Regulation	1
Cellular response to starvation	1
Response of endothelial cells to shear stress	1
Dengue Virus-Host Interactions	1
Immune System	1
Signaling by Receptor Tyrosine Kinases	1

GO top-level categories

51 GO namespaces:

Category	Terms
TOR signaling	3
cellular anatomical structure	3
cellular response to stress	2
TOR complex	2
organelle organization	1
autophagy	1
negative regulation of catabolic process	1
regulation of autophagy	1
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
positive regulation of cellular process	1
response to nutrient levels	1
cellular response to stimulus	1
intracellular signal transduction	1
regulation of TOR signaling	1
positive regulation of intracellular signal transduction	1
actin cytoskeleton organization	1
regulation of actin filament-based process	1
regulation of cytoskeleton organization	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
glycolytic process	1
regulation of glycolytic process	1
positive regulation of purine nucleotide catabolic process	1
positive regulation of carbohydrate metabolic process	1
positive regulation of ATP metabolic process	1
lipid biosynthetic process	1
positive regulation of biosynthetic process	1
positive regulation of lipid metabolic process	1
regulation of lipid biosynthetic process	1
response to hypoxia	1
cellular response to decreased oxygen levels	1
response to osmotic stress	1
cellular response to chemical stress	1
cellular response to abiotic stimulus	1
pentose-phosphate shunt	1
regulation of pentose-phosphate shunt	1
positive regulation of purine nucleotide metabolic process	1
protein binding	1
molecular adaptor activity	1
protein serine/threonine kinase activity	1
protein kinase activator activity	1
protein kinase activity	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
lysosome	1
lytic vacuole membrane	1
cytoplasm	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 26 annotations. The rest are phylogenetic / computational / electronic (IEA).

8 experimentally-supported GO terms:

GO term	NS	Evidence
TORC1 signaling	BP	direct assay
TORC2 signaling	BP	direct assay
positive regulation of TOR signaling	BP	mutant phenotype
regulation of actin cytoskeleton organization	BP	mutant phenotype
TORC1 complex	CC	direct assay
TORC2 complex	CC	direct assay
protein serine/threonine kinase activator activity	MF	direct assay
protein-macromolecule adaptor activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,678 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MLST8	RPTOR	Q8N122	992
MLST8	RICTOR	Q6R327	969
MLST8	DEPTOR	Q8TB45	922
MLST8	MAPKAP1	Q9BPZ7	921
MLST8	MTOR	P42345	918
MLST8	AKT1S1	Q96B36	893
MLST8	SEC13	P55735	889
MLST8	RPS6KB1	P23443	885
MLST8	PRR5	P85299	858
MLST8	RHEB	Q15382	851
MLST8	EIF4EBP1	Q13541	848
MLST8	FKBP1A	P20071	840
MLST8	RPS6	P08227	793
MLST8	TTI1	O43156	788
MLST8	RRAGA	Q7L523	780

IntAct

Human interaction partners of MLST8 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

15 partners by confidence:

Partner	Interaction type	MIscore	Records
MTOR	physical association	0.850	3
RPTOR	physical association	0.560	2
CCT2	association	0.530	1
APPL2	physical association	0.490	2
NUDC	physical association	0.400	1
ATXN1	physical association	0.370	2
E7	physical association	0.370	2
A2M	physical association	0.370	1
PRMT1	physical association	0.370	1
TCP1	association	0.350	1
ZNF609	association	0.350	1
LCOR	physical association	0.000	1
THADA	physical association	0.000	1
XPO4	physical association	0.000	1
XPO6	physical association	0.000	1

BioGRID (218 interactions; top human partners by supporting records): MTOR (Affinity Capture-Western; 33 records), RPTOR (Affinity Capture-Western; 17 records), RICTOR (Affinity Capture-Western; 15 records), CCT2 (Affinity Capture-MS; 5 records), KEAP1 (Affinity Capture-MS; 5 records), CCT7 (Affinity Capture-MS; 4 records), MAPKAP1 (Affinity Capture-Western; 4 records), CCT6B (Affinity Capture-MS; 3 records), FBXW7 (Affinity Capture-MS; 3 records), ACAT2 (Affinity Capture-MS; 2 records), CCT3 (Affinity Capture-MS; 2 records), CDK1 (Reconstituted Complex; 2 records), CLMP (Affinity Capture-MS; 2 records), ETV3 (Affinity Capture-MS; 2 records), FOXF2 (Affinity Capture-MS; 2 records)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
MLST8	“form complex”	mTORC1	binding
MLST8	“form complex”	mTORC2	binding

Protein complexes (CORUM) (13)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

13 complexes by size:

Complex	Subunits	Members
★ mTORC1-TFEB-Rag-Ragulator complex	11	LAMTOR2, LAMTOR4, LAMTOR5, RPTOR, RRAGC, LAMTOR1, LAMTOR3, MLST8, MTOR, RRAGA, TFEB
★ DEPTOR-mTORC2 complex	5	DEPTOR, MLST8, MTOR, RPTOR, AKT1S1
★ DEPTOR-mTORC1 complex	5	AKT1S1, DEPTOR, MLST8, MTOR, RICTOR
★ mTORC1-TELO2-TTI1 complex	5	RPTOR, TELO2, TTI1, MLST8, MTOR
★ mTORC2-TELO2-TTI1 complex	5	RICTOR, TELO2, TTI1, MLST8, MTOR
★ mTORC1-RRAGB-RRAGC complex	5	MLST8, MTOR, RPTOR, RRAGB, RRAGC
★ mTORC1-RRAGB-RRAGD complex	5	RPTOR, RRAGB, RRAGD, MLST8, MTOR
★ mTORC2-PRR5 complex	5	PRR5, RICTOR, MAPKAP1, MLST8, MTOR
★ mTORC2-PRR5L complex	5	PRR5L, RICTOR, MAPKAP1, MLST8, MTOR
★ mTORC2 complex (MAPKAP1, MLST8, MTOR, RICTOR)	4	MAPKAP1, MLST8, MTOR, RICTOR
★ mTORC1-PRAS40 complex	4	AKT1S1, MLST8, MTOR, RPTOR
★ mTOR2 complex (MTOR, RICTOR, MLST8)	3	MTOR, RICTOR, MLST8
★ mTORC1 complex (MLST8, MTOR, RAPTOR)	3	RPTOR, MLST8, MTOR

Disease & clinical

Genetic variants

Variant evidence for MLST8: 48 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	3
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 37 predictions of 850):

Position(s)	Effect	Δscore	Sites
16:2206660–2206661	donor_loss	1.0000	5
16:2207346–2207347	donor_loss	1.0000	6
16:2207350	donor_loss	1.0000	3
16:2208549	donor_gain	1.0000
16:2208614–2208615	donor_loss	1.0000	5
16:2205513–2205514	donor_loss	0.9900	4
16:2207111–2207112	donor_loss	0.9900	5
16:2207191–2207192	acceptor_loss	0.9900	6
16:2207321	donor_gain	0.9900
16:2208360	donor_gain	0.9900

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (validation)	unfavorable	0.000305
Pancreatic Adenocarcinoma (validation)	unfavorable	0.000543
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	0.00094

Disease associations

OMIM: gene MIM:612190 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST008163_267	Height	7e-7

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL4296661 (PROTEIN COMPLEX), CHEMBL4523999 (PROTEIN COMPLEX), CHEMBL6067530 (SINGLE PROTEIN)

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes MLST8 — the drug acts on the assembly or class, not necessarily on this subunit alone.

1 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
INDOXIMOD	mTORC1	3	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 277,263 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

13 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1908360	EVEROLIMUS	4	74,649
CHEMBL413	SIROLIMUS	4	174,652
CHEMBL1879463	DACTOLISIB	3	8,349
CHEMBL4084907	BIMIRALISIB	2	1,722
CHEMBL3586573	CC-115	2	1,300
CHEMBL1236962	OMIPALISIB	2	4,170
CHEMBL3586404	ONATASERTIB	2	1,138
CHEMBL3120215	OSI-027	2	1,950
CHEMBL3813842	PAXALISIB	2	1,149
CHEMBL3545097	SAPANISERTIB	2	2,649
CHEMBL2336325	VISTUSERTIB	2	2,054
CHEMBL1801204	AZD-8055	1	3,479
CHEMBL5314926	RMC-5552	1	2

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

134 measured of 179 human assays (182 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL5420034	IC50	0.02 nM
CHEMBL5429186	IC50	0.03 nM
CHEMBL5430111	IC50	0.13 nM
CHEMBL5422529	IC50	0.14 nM
CHEMBL5441038	IC50	0.14 nM
CHEMBL5404497	IC50	0.16 nM
RMC-5552	IC50	0.17 nM
CHEMBL5419721	IC50	0.19 nM
CHEMBL5399980	IC50	0.19 nM
CHEMBL5430354	IC50	0.22 nM
CHEMBL5413401	IC50	0.23 nM
CHEMBL5408375	IC50	0.24 nM
CHEMBL5422229	IC50	0.24 nM
CHEMBL5404617	IC50	0.26 nM
CHEMBL5427995	IC50	0.27 nM
CHEMBL5440792	IC50	0.28 nM
CHEMBL5394998	IC50	0.29 nM
CHEMBL5219718	KI	0.3 nM
CHEMBL5419762	IC50	0.37 nM
3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(2S)-4-methylpentan-2-yl]pyrazolo[3,4-d]pyrimidine-4,6-diamine	KI	0.4 nM	US-11731973: Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors
CHEMBL5422165	IC50	0.42 nM
CHEMBL5425648	IC50	0.47 nM
CHEMBL5434290	IC50	0.49 nM
CHEMBL5218590	KI	0.5 nM
CHEMBL5220536	KI	0.58 nM
CHEMBL5416606	IC50	0.59 nM
CHEMBL5220152	KI	0.6 nM
CHEMBL5220948	KI	0.6 nM
CHEMBL5418134	IC50	0.61 nM
CHEMBL5218916	KI	0.8 nM
3-(2-amino-1,3-benzoxazol-5-yl)-1-[(2S)-4-methylpentan-2-yl]pyrazolo[3,4-d]pyrimidine-4,6-diamine	KI	0.8 nM	US-11731973: Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors
CHEMBL4453693	KD	0.84 nM
CHEMBL5424277	IC50	0.93 nM
Sapanisertib	IC50	1 nM	US-10172858: Combination pharmaceutical compositions and uses thereof
CHEMBL2338395	IC50	1 nM
CHEMBL2338394	IC50	1 nM
CHEMBL4563142	IC50	1 nM
CHEMBL4445573	KI	1.9 nM
CHEMBL3813842	IC50	2 nM
CHEMBL5218988	KI	2 nM
5-(2-aminobenzoxazol-5-yl)-7-methyl-7-methylsulfanylmethyl-6, 7-dihydro-5H-pyrrolo[3,2-d]pyrimidin-4-ylamine	KI	2.4 nM
CHEMBL4758284	KI	2.7 nM
CHEMBL4749136	KI	3.4 nM
CHEMBL5218737	KI	3.9 nM
5-(7-methyl-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine	IC50	4 nM
CHEMBL4754767	KI	4.4 nM
1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one	IC50	6.3 nM
(S)-5-(4-morpholino-5a,6,8,9-tetrahydro-5H- pyrimido[5’,4’:4,5]pyrrolo[2,1-c][1,4]oxazin-2- yl)pyrimidin-2-amine	KI	8 nM	US-9556191: Aminoquinazoline derivatives and their salts and methods of use thereof
5-(2-aminobenzoxazol-5-yl)-7-isobutyl-6, 7-dihydro-5H-pyrrolo[3,2-d]pyrimidin-4-ylamine	KI	12 nM
CHEMBL5420465	IC50	13 nM

ChEMBL bioactivities

385 potent at pChembl≥5 of 387 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.70	IC50	0.02	nM	CHEMBL5420034
10.52	IC50	0.03	nM	CHEMBL5429186
10.40	IC50	0.04	nM	CHEMBL5418335
10.30	IC50	0.05	nM	SIROLIMUS
10.30	IC50	0.05	nM	EVEROLIMUS
10.22	IC50	0.06	nM	SIROLIMUS
10.22	IC50	0.06	nM	CHEMBL5420034
10.15	IC50	0.07	nM	EVEROLIMUS
10.10	IC50	0.08	nM	CHEMBL5429186
10.00	IC50	0.1	nM	CHEMBL5218737
9.89	IC50	0.13	nM	CHEMBL5430111
9.85	IC50	0.14	nM	CHEMBL5422529
9.85	IC50	0.14	nM	CHEMBL5441038
9.80	IC50	0.16	nM	CHEMBL5404497
9.77	IC50	0.17	nM	RMC-5552
9.74	Ki	0.18	nM	OMIPALISIB
9.74	IC50	0.18	nM	OMIPALISIB
9.72	IC50	0.19	nM	CHEMBL5419721
9.72	IC50	0.19	nM	CHEMBL5399980
9.70	IC50	0.2	nM	CHEMBL5219718
9.70	IC50	0.2	nM	CHEMBL5218916
9.66	IC50	0.22	nM	CHEMBL5430354
9.64	IC50	0.23	nM	CHEMBL5413401
9.62	IC50	0.24	nM	CHEMBL5408375
9.62	IC50	0.24	nM	CHEMBL5422229
9.60	EC50	0.25	nM	CHEMBL1765602
9.59	IC50	0.26	nM	CHEMBL5404617
9.57	IC50	0.27	nM	CHEMBL5427995
9.55	IC50	0.28	nM	CHEMBL5440792
9.54	IC50	0.29	nM	CHEMBL5394998
9.54	IC50	0.29	nM	TORIN1
9.52	Ki	0.3	nM	OMIPALISIB
9.43	IC50	0.37	nM	CHEMBL5419762
9.43	IC50	0.37	nM	CHEMBL5431157
9.38	IC50	0.42	nM	CHEMBL5422165
9.38	IC50	0.42	nM	CHEMBL5419721
9.36	IC50	0.44	nM	CHEMBL5430111
9.36	IC50	0.44	nM	CHEMBL5441038
9.33	IC50	0.47	nM	CHEMBL5425648
9.32	IC50	0.48	nM	CHEMBL5422529
9.31	IC50	0.49	nM	CHEMBL5434290
9.30	IC50	0.5	nM	CHEMBL5218727
9.23	IC50	0.59	nM	CHEMBL5416606
9.21	IC50	0.61	nM	CHEMBL5418134
9.17	IC50	0.67	nM	CHEMBL5404497
9.16	IC50	0.69	nM	SAPANISERTIB
9.15	IC50	0.7	nM	CHEMBL2334767
9.15	IC50	0.7	nM	CHEMBL5218590
9.15	IC50	0.7	nM	CHEMBL5220152
9.15	IC50	0.7	nM	CHEMBL5413401

PubChem BioAssay actives

403 with measured affinity, of 757 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18-trihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,20-tetrone	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	<0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4R)-3-methoxy-4-[4-[1-[2-[2-[2-[2-[2-[2-[2-[2-[3-[4-[4-[8-(6-methoxy-3-pyridinyl)-1-methyl-2-oxoimidazo[4,5-c]quinolin-3-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]butoxy]cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	<0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4R)-3-methoxy-4-[4-[1-[2-[2-[2-[2-[2-[2-[3-[4-[4-[8-(6-methoxy-3-pyridinyl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-1-yl]-2-(trifluoromethyl)phenyl]piperazin-1-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]butoxy]cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	<0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-30-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-30-(1,4,7,10-tetraoxacyclododec-2-ylmethoxy)-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-30-[2-(2-hydroxyethoxy)ethoxy]-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-30-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-30-[2-[2-(2-hydroxyethylsulfanyl)ethylsulfanyl]ethoxy]-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-[4-[1-[2-[2-[2-[2-[2-[2-[2-[2-[3-[6-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]butoxy]-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0001	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-14,19,30-trimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[6-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0001	uM
(1R,9S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30R,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,2R,4R,5R)-5-hydroxy-2-bicyclo[2.2.1]heptanyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916680: Inhibition of mTORC1 in human Jurkat cells assessed as inhibition of S6K phosphorylation incubated for 4 hrs by Western blot analysis	ic50	0.0001	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-14,19,30-trimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[2-[4-[7-(6-amino-3-pyridinyl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carbonyl]-2-fluoro-3-methylphenyl]sulfonylethylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0001	uM
Sirolimus	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
Everolimus	1916668: Inhibition of mTORC1 (unknown origin)	ic50	0.0001	uM
3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine	1916693: Inhibition of mTORC1 in human A-431 cells assessed as phosphorylated S6RP level incubated for 3 hrs by HTRF assay	ic50	0.0002	uM
3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-(2,2-dimethylbutyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine	1916693: Inhibition of mTORC1 in human A-431 cells assessed as phosphorylated S6RP level incubated for 3 hrs by HTRF assay	ic50	0.0002	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-[4-[1-[2-[2-[2-[2-[2-[2-[2-[2-[3-[4-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]piperidin-1-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]butoxy]-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
N-[4-[4-amino-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
N-[4-[4-amino-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
[(1R,2R,4S)-2-methoxy-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18-trihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]cyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[6-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[6-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
[(1R,2R,4S)-2-methoxy-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18-trihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]cyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[2-[4-[7-(6-amino-3-pyridinyl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carbonyl]-2-fluoro-3-methylphenyl]sulfonylethylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[2-[4-[7-(6-amino-3-pyridinyl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carbonyl]-2-fluoro-3-methylphenyl]sulfonylethylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
[(1R,2R,4S)-2-methoxy-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18-trihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]cyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0002	uM
2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)-3-pyridinyl]benzenesulfonamide	1871789: Inhibition of mTORC2 (unknown origin)	ic50	0.0002	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,32S,35R)-1,18-dihydroxy-30-(2-hydroxyethoxy)-19-methoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-(2-phenylethyl)carbamate	1916670: Inhibition of mTORC1 in human PC-3 cells assessed as measuring phosphorylated S6K level incubated for 24 hrs by AlphaLISA assay	ic50	0.0003	uM
N-[4-[4-amino-3-(5-hydroxy-1H-indol-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0003	uM
N-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0003	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,32S,35R)-1,18-dihydroxy-30-(2-hydroxyethoxy)-19-methoxy-12-[(2R)-1-[(1S,3R,4R)-3-methoxy-4-[3-[(3S)-3-methylmorpholin-4-yl]propoxy]cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916670: Inhibition of mTORC1 in human PC-3 cells assessed as measuring phosphorylated S6K level incubated for 24 hrs by AlphaLISA assay	ic50	0.0003	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-[3-[(2S,6R)-2,6-dimethylmorpholin-4-yl]propoxy]-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-30-(2-hydroxyethoxy)-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916670: Inhibition of mTORC1 in human PC-3 cells assessed as measuring phosphorylated S6K level incubated for 24 hrs by AlphaLISA assay	ic50	0.0003	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,32S,35R)-1,18-dihydroxy-30-(2-hydroxyethoxy)-19-methoxy-12-[(2R)-1-[(1S,3R,4R)-3-methoxy-4-[3-[(3R)-3-methylmorpholin-4-yl]propoxy]cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916670: Inhibition of mTORC1 in human PC-3 cells assessed as measuring phosphorylated S6K level incubated for 24 hrs by AlphaLISA assay	ic50	0.0003	uM
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-[3-(2,2-dimethylmorpholin-4-yl)propoxy]-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-30-(2-hydroxyethoxy)-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone	1916670: Inhibition of mTORC1 in human PC-3 cells assessed as measuring phosphorylated S6K level incubated for 24 hrs by AlphaLISA assay	ic50	0.0003	uM
N-[4-[3-(2-amino-1,3-benzoxazol-5-yl)-4-(dimethylamino)pyrazolo[5,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0003	uM
8-(6-methoxy-3-pyridinyl)-1-methyl-3-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0003	uM
1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one	1994242: Inhibition of mTORC1 (unknown origin)	ic50	0.0003	uM
9-(6-amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one	1512676: Inhibition of mTORC1 in human HCT116 cells assessed as reduction in T389 phosphorylation on RPS6KB1 after 1 hr by Western blot analysis	ec50	0.0003	uM
(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-14,19,30-trimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,20-tetrone	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0004	uM
N-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0004	uM
N-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0004	uM
N-[4-[4-amino-3-(5-hydroxy-1H-indol-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxyethoxymethyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0005	uM
3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(2S)-4-methylpentan-2-yl]pyrazolo[3,4-d]pyrimidine-4,6-diamine	1916693: Inhibition of mTORC1 in human A-431 cells assessed as phosphorylated S6RP level incubated for 3 hrs by HTRF assay	ic50	0.0005	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-14,19,30-trimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0005	uM
N-[4-[4-amino-3-(5-hydroxy-1H-indol-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[4-[4-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxybutyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0006	uM
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butylamino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0006	uM
N-[5-[4,6-diamino-1-(2,2-dimethylbutyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-yl]acetamide	1916693: Inhibition of mTORC1 in human A-431 cells assessed as phosphorylated S6RP level incubated for 3 hrs by HTRF assay	ic50	0.0007	uM
3-(2-amino-1,3-benzoxazol-5-yl)-1-(2,2-dimethylpropyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine	1916693: Inhibition of mTORC1 in human A-431 cells assessed as phosphorylated S6RP level incubated for 3 hrs by HTRF assay	ic50	0.0007	uM
Sapanisertib	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0007	uM
2-[(1R,9S)-4-[4-(ethylcarbamoylamino)phenyl]-6-[(3S)-3-methylmorpholin-4-yl]-3,5,12-triazatricyclo[7.2.1.02,7]dodeca-2(7),3,5-trien-12-yl]-N,2-dimethylpropanamide	730846: Inhibition of mTORC1 in human NCI-PC3 cells assessed as inhibition of p70S6K phosphorylation	ic50	0.0007	uM
[5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol	1512672: Inhibition of mTORC1 (unknown origin)	ic50	0.0008	uM
N-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxyethoxymethyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide	1964503: Inhibition of mTORC1 in human MDA-MB-468 cells assessed as reduction in P70S6K phosphorylation at Thr389 by AlphaLISA assay	ic50	0.0009	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	3
Valproic Acid	decreases expression, increases methylation	2
aristolochic acid I	decreases expression	1
TAK-243	increases sumoylation	1
bisphenol A	decreases expression	1
trichostatin A	affects expression	1
beta-lapachone	increases expression	1
cobaltous chloride	decreases expression	1
4-phenylenediamine	decreases expression	1
sulphoraphene	decreases expression	1
bisphenol B	increases expression	1
jinfukang	increases expression	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Air Pollutants	affects expression, affects methylation, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1
Selenium	increases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

275 unique, capped per target: 275 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1104625	Binding	Inhibition of mTORC1 dependent P-S6K T389 phosphorylation in human U87MG cells after 6 hrs by immunoblot	Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. — *J Med Chem*

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1DU	Abcam HCT 116 MLST8 KO	Cancer cell line	Male
CVCL_SY55	HAP1 MLST8 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for MLST8 across ~30M SureChEMBL compounds — explore on Sugi Predict.